Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.

Jeremie Calais,Shaojun Zhu,Nader Hirmas,Matthias Eiber,Boris A. Hadaschik,Martin Stuschke,Ken Herrmann,Johannes Czernin,Amar U. Kishan,Nicholas G. Nickols,David Elashoff,Wolfgang P. Fendler

Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.

2021

Jeremie Calais
Shaojun Zhu
Nader Hirmas
Matthias Eiber
Boris A. Hadaschik
Martin Stuschke
Ken Herrmann
Johannes Czernin
Amar U. Kishan
Nicholas G. Nickols
David Elashoff
Wolfgang P. Fendler

TPS172Background: Definitive radiation therapy (dRT) is an effective initial treatment of intermediate-risk (IR) and high-risk (HR) prostate cancer (PCa). Positron emission tomography (PET) using s...

Keywords:

Oncology
Prostate cancer
Positron emission tomography
intermediate risk
psma pet
initial treatment
Randomized controlled trial
Internal medicine
Medicine
Definitive Radiation Therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations